SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Human Genome Sciences, Inc. (HGSI)
An SI Board Since March 1996
Posts SubjectMarks Bans Symbol
1127 105 0 HGSI
Emcee:  Jeffrey Ogbar Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
877Thanks for reposting my Yahoo post, Bob. I was just about to repost it here (afSteven Rachbach-11/17/2005
876Human Genome Sciences Reports Results of Phase 1 Clinical Trials of HGS-ETR2 in bob zagorin-11/17/2005
875reposted from yahoo Anti-BLyS for RA/SLE (P1) by: steverachbach (47/M/Tucson, Abob zagorin-11/17/2005
874Help Is on the Way for Hepatitis C By JOHANNA BENNETT IT STRIKES MORE AMERICANSbob zagorin-11/16/2005
873Human Genome Sciences Reports Interim Results of Phase 2 Clinical Trial of Albufbob zagorin-11/15/2005
872There hasn't been a new drug approved to treat lupus in 40 years. [The Bostobob zagorin-11/14/2005
871new coverage Human Genome HGSI Citigroup Buy $12bob zagorin-11/9/2005
870Human Genome Sciences Calls for Redemption All of Its Remaining Outstanding Subobob zagorin-11/8/2005
869[BLyS and APRIL in rheumatoid arthritis] jci.org Full text freebie. Cheers, tuck-11/3/2005
868HGSI’s HGS-ETR1 fails to generate any responses in advanced colorectal cancer: DewDiligence_on_SI-11/1/2005
867Thanks for clarifying that. I caught only the last part of the question period A.J. Mullen-10/7/2005
866Outlook Turns Cloudy for Human Genome Human Genome Sciences Inc. (HGSI: Nasdaq)bob zagorin-10/7/2005
865<<I agree that the rationale for excluding non-seropositives seems reasonaSteven Rachbach-10/7/2005
864Yes, natural variation reduces the power of the test, that's why it was suchA.J. Mullen-10/6/2005
863<i>significance can't be too robust if it is lost by dilution of only Biomaven-10/6/2005
862I sold my remaining shares just before the close. No significant difference wA.J. Mullen-10/5/2005
861Human Genome Sciences Reports Results of a Phase 2 Clinical Trial of LymphoStat-A.J. Mullen-10/5/2005
860GlaxoSmithKline Exercises Option to Human Genome Sciences' Trail Receptor Annigel bates-8/18/2005
859Human Genome Sciences Receives Milestone Payments from GlaxoSmithKline for GSK71A.J. Mullen-8/1/2005
858Human Genome Sciences Publishes Results of Phase 1 Clinical Trial of ABthrax(TM)nigel bates-7/18/2005
857(Comment from Forbes, FWIW...) ....Thursday morning, Human Genome Sciences (nasnigel bates-7/7/2005
85617-AAG overcomes TRAIL resistance in colon cancer cell lines Message 21482885nigel bates-7/7/2005
855GlaxoSmithKline Exercises Option to LymphoStat-B(TM) Thursday July 7, 7:00 am ETnigel bates-7/7/2005
854Human Genome Sciences Reports Results of Phase 2 Clinical Trial of HGS-ETR1 In Pnigel bates-7/5/2005
853Human Genome Sciences Reports Interim Results of Phase 2 Clinical Trial of HGS-Enigel bates-6/13/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News